Fulcrum Therapeutics, Inc. FULC
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
Fulcrum Therapeutics, Inc. (FULC) is a healthcare company listed in the US with a market value of about $288M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -27%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 40% below the current price.
About Fulcrum Therapeutics
Fulcrum Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. Revenue went from $9M in 2020 to $80M in 2024, growth of about 73.5% a year. It was profitable in 0 of the last 8 years in our data. Its share count rose by 41% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $80M | $3M | $6M | $19M | $9M | — | — |
| Net income | -$75M | -$10M | -$97M | -$110M | -$81M | -$71M | -$83M | -$33M |
| Free cash flow | -$60M | -$2M | -$91M | -$99M | -$80M | -$55M | -$40M | -$32M |
| EPS (diluted) | $-1.18 | $-0.16 | $-1.59 | $-2.44 | $-2.29 | $-2.79 | $-8.13 | $-31.14 |
| Net margin | — | -12.2% | -3470.0% | -1732.4% | -421.9% | -802.7% | — | — |
| ROIC | -18.8% | -6.9% | -35.5% | -41.9% | -30.3% | -59.4% | -76.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $3.67, 3% below the current price; targets range from $3.00 to $4.00; the consensus rating is “Hold”; expected EPS is $-0.84 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Fulcrum Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 40% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Fulcrum Therapeutics pay a dividend?
Not currently.
Is Fulcrum Therapeutics a good stock to buy?
We do not give buy or sell advice. Fulcrum Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.